Copy number variation (CNV) is the term used to describe genomic structural variations ranging in size from kilobases (kb) to Megabases (Mb). The recent extensive utilization of genome-wide study tools such as comparative genomic hybridization (CGH) has led to the rapid expansion of these studies (1) (2) (3) . Altering the copy number of dosage-sensitive regions has been well established as a mechanism leading to clinically relevant phenotypes (4) , and since the early 1980s, a number microscopic deletion syndromes have been described. Microdeletion of chromosome 15q11.2q12 was identified as a cause of Prader-Willi syndrome, and reports of other disorders that contain variable deletion break points followed, such as α-thalassemia and Duchenne muscular dystrophy (5) (6) (7) (8) . Owing to the lack of accurate molecular tools that screened the whole genome for CNVs 1-50 kb in size (3, 9) , investigators focused their search to previously identified regions of disease-predisposing genes, which enabled localization of smaller CNVs. This approach proved fruitful in identifying CNVs as the cause of a number of common complex traits such as Parkinson's disease, Alzheimer's disease and epilepsy (10) (11) (12) (13) .
Juvenile polyposis (JP) is an autosomal dominant disorder characterized by the development of multiple hamartomatous polyps of the gastrointestinal (GI) tract (14, 15) . JP carries an increased risk of GI malignancy, with a lifetime risk of approximately 50% (16) . In 1998, a JP gene was localized to chromosome 18q21 by linkage analysis and germline mutations were found in the tumor suppressor gene SMAD4 in several families (17, 18) . In 2001, another JP locus was found in four kindreds mapping to chromosome 10q22-23. Germline mutations were identified in the bone morphogenetic protein receptor type 1A (BMPR1A), a receptor involved in the BMP signaling pathway, of which SMAD4 is the intracellular mediator (19) . Prior to this, mutations in the tumor suppressor gene PTEN, also located on 10q22-23, about 1Mb telomeric to BMPR1A, had been found in the germline of patients with Cowden syndrome (CS), in which some patients also develop hamartomatous intestinal polyps (20, 21) .
Prior to the discovery of BMPR1A as a JP gene, there were two reports of JP patients with PTEN germline mutations (22, 23) . However, further review of the clinical data suggested these patients might have CS rather than JP, and Eng and Ji concluded that patients with inherited hamartoma syndromes and PTEN mutations should be considered to have CS or Bannayan-RileyRuvalcaba syndrome (BRRS) (24) . Besides BRRS, it later became evident that PTEN mutations were present in the other distinct hamartomatous syndromes, Proteus syndrome and Proteus-like syndrome ((25, 26) and reviewed in Ref. (27) ).
Owing to the phenotypic diversity exhibited by patients with PTEN mutations and the fact that germline single base substitutions and small deletion/insertions in the JP genes BMPR1A and SMAD4 only account for less than half of JP cases (28, 29) , alternative means of gene inactivation have been explored. This was largely facilitated by the improvement and increased availability of molecular tools that identify smaller-scale CNVs. Multiplex ligationdependent probe amplification (MLPA) is one method by which many genomic deletions/duplications have been found in target genes (30) (31) (32) (33) , and this technique has been particularly useful in the study of JP-related CNVs. Here we review the literature for studies that describe chromosome 10q22-23 microdeletions in JP and other intestinal polyposis syndromes.
JP, CS and BRRS
Three subtypes of JP were defined by Sachatello et al. in 1975: (i) juvenile polyposis coli (JPC), (ii) generalized juvenile polyposis (GJP), and (iii) juvenile polyposis of infancy (JPI) (34) . The first two subtypes are distinguished by the location and extent of polyps along the GI tract with JPC having polyps in the colon only and GJP in the colon and upper GI tract. These are thought to be variable manifestations of the same condition as both subtypes can be present in the same families and commonly present in the first two decades of life (35) . In contrast, JPI is characterized by a very early age of onset (often before 2 years of age) and a substantially more severe clinical course because of recurrent GI bleeding, diarrhea and exudative enteropathy. JPI has rarely been reported in the literature, and the infrequency of this condition and its high rate of mortality have limited the study of its molecular basis in the past.
CS was first described in 1963 by Lloyd et al. (36) . It is autosomal dominant and is characterized by the formation of multiple disorganized benign growths (hamartomas) and an increased risk of benign and malignant tumor development. More than 90% of affected patients manifest the phenotype before 20 years of age and almost all have CS-mucocutaneous involvement (37) . Of note, thyroid abnormalities occur in over 50% of cases, 38% have macrocephaly and 40% develop GI hamartomatous polyps. Clinical diagnosis is often challenging, and can be aided by genetic testing (37) . BRRS is a rare disorder that also has an autosomal dominant mode of transmission, and affected members manifest with macrocephaly, lipomatosis, angiomatosis, penile abnormalities and occasional intestinal polyps (38) . It is estimated that 60% of BRRS cases have germline mutations in PTEN and some cases even overlap with CS from a clinical perspective (25) . The correlation between genotype and phenotype in these two syndromes is not fully understood, and there is overlap of mutations suggesting that the two conditions are allelic (39) .
Cytogenetic studies
The first report to describe a germline chromosomal anomaly in a patient with a hamartomatous polyposis syndrome came from Jacoby et al. in 1997 (40) . The authors described a 4-year-old boy referred for a 1-year history of hematochezia who had several dozen polyps of typical juvenile histology distributed along the colon on endoscopy. This patient had multiple congenital abnormalities including dysmorphic features, as well as growth and developmental delay which suggested the presence of a chromosomal abnormality. Using a standard Giemsa-banding method, metaphase analysis of peripheral leukocytes revealed an interstitial deletion of the long arm of chromosome 10, with a karyotype of 46,XY,del(10)(q22.3.24.1). This change was de novo, as cytogenetic analysis did not reveal a similar abnormality in either parent. Figure 1 illustrates the locations of the different deletions reported here and in subsequent studies.
Later that year, Arch et al. reported a similar case (42) . The authors described an 18-month-old boy with a presumed diagnosis of BRRS who had multiple anomalies consistent with that diagnosis, such as remarkable macrosomia that was 7 SD above the ageadjusted mean, two lipomas, developmental delay and pseudopapilledema. On endoscopy, multiple hamartomatous polyps that extended throughout the duodenum and small intestine were found, and as polyps in BRRS are usually confined to the distal ileum and colon, the authors proposed that features of CS might overlap in this patient. Standard Giemsa banding was used for the karyotyping, which revealed a hemizygous deletion of chromosome 10q23.2-q24.1. The authors further showed the absence of PTEN by performing fluorescence in situ hybridization (FISH) using a bacterial artificial chromosome (BAC) clone specific for that gene. Examination of the parental chromosomes revealed no abnormalities.
Zigman et al. reported two additional patients soon afterward (41) . The first patient they described was a male who presented with developmental delay, macrocephaly, a subcutaneous hamartoma and multiple juvenile polyps in the intestine, features thought to be typical of BRRS. The second patient was a girl who additionally had complex congenital cardiac anomalies, as well as clubfoot. Both patients had abnormal karyotypes by Geimsa-staining. The deletion in the first patient was part of an unbalanced translocation with the distal short arm of chromosome 9 (41) were studied by Giemsa banding only and the exact positions of the breakpoints were therefore not determined. BMPR1A and PTEN are within gray boxes. Numbers next to the author names refer to the individual cases in the order that they were listed in their corresponding primary publications.
[46,XY,der(9)t(9;10)(p24.1;q24.1),der(10)del(10)(q23. 2q24.1)t(9;10)(p24.1;q23.2)], and in the second patient was a simple deletion [46,XX,del(10)(q23.1q24.2)]. Chromatin loss was confirmed in both patients; however, the deletion was substantially larger in the second patient (11.6 cM) compared to the first (∼1 cM). As the diagnosis of JP was highly suspected in the second patient, the authors concluded that genes responsible for JP and BRRS were within that chromosomal segment. In both patients, the parental karyotypes were normal.
In 1998, Tsuchiya et al. reported another case of a 6-year-old boy with rectal bleeding since the age of 2 (43) . He was found to have multiple juvenile polyps that extended from the duodenum to the rectum. Other clinical features included developmental delay, prominent dysmorphic facies, a large head circumference (>90th percentile) and hyperpigmentation of the mouth and penis. Cytogenetic analysis of Giemsa/Trypsin/Leishman-banded chromosomes revealed a karyotype of 46,XY,del(10)(q23.2q23.33), and the estimated size of the deletion was between 11 and 15 cM by FISH. BRRS was thought to be unlikely in this patient as there was no evidence of lipomas or hemangiomas. Moreover, CS was not confirmed either because of the lack of characteristic findings such as papillomatous skin lesions, thyroid or genitourinary abnormalities. Other family members reportedly had no such signs, and the mother's karyotype was found to be normal.
In 2005, Delnatte et al. described four unrelated cases of JPI who had deletions of both BMPR1A and PTEN (44) . All patients presented at an early age (between 1 and 18 months) and had multiple juvenile polyps extending throughout the upper and lower GI tracts. Furthermore, they all had macrocephaly, but hemangiomas were only found in two of the four. Facial dysmorphism was present in three patients and none showed evidence of mental retardation (other features are summarized in Table 1 ). FISH was performed using BAC clones encompassing PTEN and BMPR1A in the first three patients, which confirmed loss of this region. In patient 4, quantitative polymerase chain reaction (PCR) of all BMPR1A and PTEN exons showed the complete loss of both genes. Interestingly, one patient was mosaic for this deletion, exhibiting it in only 17% of examined peripheral lymphocytes. Using CGH and serial microsatellite typings, the deletions in patients 1, 2 and 4 were further characterized and found to be between 1.2 and 2 Mb in length. In two of these patients, genetic testing revealed no abnormalities in either parent (data was not available from the other two patients).
These reports gave rise to the hypothesis that the more aggressive JPI is caused by deletion of the two contiguous genes known to cause JP, CS and BRRS (BMPR1A and PTEN ). However, clinical and molecular data were not always consistent, as features associated with BRRS, such as macrocephaly, facial dysmorphy, speckled penis, and lipomas were not found in all subjects thought to have JPI. A later report by Salviati et al. (46) argued the notion that a more complex mechanism underlies the development of JPI, and that (47), and provided valuable insight on the phenotypic outcome of these deletions. The authors described four new patients with JPI who had 10q23 microdeletions that involved both BMPR1A and PTEN. All four cases had macrocephaly, dysmorphic features and other congenital abnormalities. This study was unique in that it combined data from MLPA with FISH and then further characterized the deletions by single-nucleotide polymorphism (SNP) analysis using the Affymetrix 250k NspI array. The amount of heterozygous loss of DNA ranged between 2.88 and 4.26 Mb, with larger deletions not predicting a more severe course of disease. The authors concluded that the clinical consequences of these molecular abnormalities were fairly heterogeneous.
The frequency of large deletions in JP
The first study to address the frequency of CNV in the causative genes for JP was performed by Aretz et al. in 2007 (29) . The authors examined 80 unrelated cases of JP where patients' DNA was first subjected to direct sequencing of BMPR1A, SMAD4, PTEN and CDH1. For MLPA analysis, 60 patients were examined (50 did not have any point mutations and another 10 had missense mutations or unspecified variants). DNA from these 60 probands was analyzed by MLPA kit P158 (MRC Holland, Amsterdam, the Netherlands). A total of 6/80 (7.5%) were found to have deletions in SMAD4 and 3/80 (3.8%) had deletions in BMPR1A. One of these latter patients had decreased amplification in the probes for the two first non-coding exons and first exon and another only had the first exon deleted. The third patient had a deletion of the entire genes of BMPR1A and PTEN. Further review of this patient's history revealed the age at diagnosis was 3, (possibly consistent with JPI), but additional information regarding the patient's phenotype was not reported.
A similar study by van Hattem et al. examined a well-documented group of 27 JP patients and utilized the same MLPA kit as Aretz et al. (48) . To check first for point mutations and small deletions/insertions, direct sequencing was performed and mutations in SMAD4 and BMPR1A were only found in 9 (33.3%) patients.
MLPA was subsequently used on the remaining 18 patients, and 4 large hemizygous deletions were found (one including all exons of SMAD4, one in exons 10 and 11 of BMPR1A, and 2 involving all exons of PTEN and BMPR1A). Both patients that had the contiguous deletion of BMPR1A and PTEN at 10q22-23 had typical multiple juvenile polyps; however, one of them was reported to have thyroid carcinoma making CS also a potential diagnosis. Other pertinent features and age of onset were not mentioned.
The most recent study searching for large deletions in JP probands came from our laboratory in 2009 (49) . A total of 102 subjects were analyzed, all meeting the clinical criteria set by Jass et al. (50) . Direct sequencing identified SMAD4 and BMPR1A mutations in (42/102) 41.2% of patients. The remaining 60 patients were examined by MLPA, and two patients were found to have deletions involving parts or all of SMAD4. Two patients were found to have large deletions involving BMPR1A. One involved the promoter and first noncoding exon (51) and the other a contiguous deletion of BMPR1A and PTEN. This patient did not appear to have JPI based on age of diagnosis (20 years), but had intriguing manifestations suggestive of BRRS such as macrocephaly (95th percentile head circumference), a dermatofibroma, trichoepithelioma and recurrent hernias (49) . A summary of the deletions found by MLPA in these studies is shown in Fig. 2 .
Contiguous deletions must include PTEN
In this review, we found that all patients with chromosome 10 microdeletions who presented with signs of polyposis were found to have a hemizygous deletion, which included both BMPR1A and PTEN. Further insight on that could be derived by examining two individual studies by Balciuniene (45) and Alliman (52). Balciuniene et al. reported three unrelated probands who had deletions in the 10q22.3-23.3 region. The first two probands had a deletion ∼7.2 Mb in size that included BMPR1A, but not PTEN. Both patients manifested with developmental delay and macrocephaly, and had no evidence of polyposis. The third proband was the same patient described by Arch et al. (42) in 1997. The authors confirmed the loss of both BMPR1A and PTEN in this patient and again confirmed the presence of hamartomatous polyps. Alliman et al. reported an additional six patients with deletions similar to the first two probands reported by Balciuniene et al. (52) . Likewise, none had any signs of polyposis, which suggested the requirement of a contiguous deletion of both genes for polyposis to take place. Nevertheless, because of the rarity of this condition, and the fact that point mutations and smaller deletions (detected by MLPA) in BMPR1A cause JP, the risk of polyposis in these patients with microdeletions cannot be ruled out entirely.
Summary
Mutations in BMPR1A have been found in patients with JP, whereas PTEN mutations have been described in CS and BRRS. These two genes map to chromosome 10q22-23 and contiguous deletions of both genes have been reported. We reviewed the literature for studies that describe large deletions in JP-predisposing genes and further focused on the phenotype of patients with contiguous deletions of BMR1A and PTEN.
Point mutations and small insertions/deletions in SMAD4 and BMPR1A have been identified through direct sequencing in 21.6% and 18.5% of JP cases, respectively, which suggested CNV as an alternative mechanism of inactivation of these genes. Three major independent studies utilizing MLPA have been conducted to date to screen for CNVs in patients with JP (29, 48, 49) . These collectively reported a total of 6.3% of JP patients to have large germline deletions of one of the two causative genes (BMPR1A and SMAD4 ). Despite thorough evaluation of these two genes, a significant portion of patients with the clinical diagnosis of JP remain genetically unaccounted for, which suggests that other genes might be involved in the pathogenesis of JP.
JP usually presents in older children or young adults, but when it presents at a very early age, it is associated with a more severe clinical course and more pronounced extraintestinal manifestations, often leading to a significantly reduced life expectancy. Recently, two studies attempted to correlate the extent of DNA loss with the severity of the symptoms (suggesting that the hemizygous deletion of more genes could potentially lead to more pronounced manifestations), and found no clear association (46, 47) . However, it is plausible that large deletions involving both BMPR1A and PTEN lead to a clinical picture that is more severe than JP. In addition, part of the controversy may be because of the lack of a unified diagnostic definition for JPI. Salviati et al. argued that as their patient did not present before 2 years of age with GI bleeding, diarrhea and rectal prolapse, JPI was a questionable diagnosis (46) (referring to the criteria proposed by Sachatello in 1974 (53) ). In response, Sanalville et al. argued that an age of diagnosis at 6 years points toward an onset of the disease process in infancy and that the diagnosis of JPI is appropriate (54) . The rarity and variability of these deletions has made the correlation between phenotype and genotype difficult. Nevertheless, the accumulation of these data can point researchers to study this area more closely and perhaps examine other genes in 10q22-23 in patients with features of these disorders. Finally, while the range of phenotypes is variable, we conclude that JPI is a unique entity that often combines features of both CS and BRRS with JP, and likely requires the loss of both BMPR1A and PTEN.
